| Length | Dha= Didehydroalanine, Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid, Lanthionine (Ala-S-Ala) formation from 3-7 Ala, and β-methyllanthionine (Abu-S-Ala) from 8-11, 13-19, 23-26, 25-28 in between Abu and Ala |
| Primary information |
|---|
| ID | antitb_1145, |
| Name | 21468208 |
| N-Terminal modification | Nisin A |
| C-Terminal Modification | I-(Dhb)-AI-(Dha)-LA-(Abu)-PGAK-(Abu)-GALMGANMK-(Abu)-A-(Abu)-ANASIHV-(Dha)-K |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Dha= Didehydroalanine, Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid, Lanthionine (Ala-S-Ala) formation from 3-7 Ala, and β-methyllanthionine (Abu-S-Ala) from 8-11, 13-19, 23-26, 25-28 in between Abu and Ala |
| Chirality | Cyclic (5 hinge region due to presence of lanthion |
| Nature | 34 |
| Source | L |
| Species | Natural |
| Strain | Produced by Lactococcus lactis |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Ra |
| Inhibition Concentration | In vitro |
| Sequence | 2010 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | None |
| Year of Publication | Antibacterial (Shigella, Pseudomonas and Salmonella, S. aureus, S. agalactiae and L. monocytogenes) |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1146, |
| Name | 21468208 |
| N-Terminal modification | Nisin A |
| C-Terminal Modification | I-(Dhb)-AI-(Dha)-LA-(Abu)-PGAK-(Abu)-GALMGANMK-(Abu)-A-(Abu)-ANASIHV-(Dha)-K |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Dha= Didehydroalanine, Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid, Lanthionine (Ala-S-Ala) formation from 3-7 Ala, and β-methyllanthionine (Abu-S-Ala) from 8-11, 13-19, 23-26, 25-28 in between Abu and Ala |
| Chirality | Cyclic (5 hinge region due to presence of lanthion |
| Nature | 34 |
| Source | L |
| Species | Natural |
| Strain | Produced by Lactococcus lactis |
| Inhibition Concentration | Mycobacterium kansasii |
| In Vitro/ In vivo | Mycobacterium kansasii CIT11/06 |
| Inhibition Concentration | In vitro |
| Sequence | 2010 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | None |
| Year of Publication | Antibacterial (Shigella, Pseudomonas and Salmonella, S. aureus, S. agalactiae and L. monocytogenes) |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1147, |
| Name | 21468208 |
| N-Terminal modification | Nisin A |
| C-Terminal Modification | I-(Dhb)-AI-(Dha)-LA-(Abu)-PGAK-(Abu)-GALMGANMK-(Abu)-A-(Abu)-ANASIHV-(Dha)-K |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Dha= Didehydroalanine, Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid, Lanthionine (Ala-S-Ala) formation from 3-7 Ala, and β-methyllanthionine (Abu-S-Ala) from 8-11, 13-19, 23-26, 25-28 in between Abu and Ala |
| Chirality | Cyclic (5 hinge region due to presence of lanthion |
| Nature | 34 |
| Source | L |
| Species | Natural |
| Strain | Produced by Lactococcus lactis |
| Inhibition Concentration | Mycobacterium avium |
| In Vitro/ In vivo | Mycobacterium avium subsp. Hominissuis (CIT05/03) |
| Inhibition Concentration | In vitro |
| Sequence | 2010 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | None |
| Year of Publication | Antibacterial (Shigella, Pseudomonas and Salmonella, S. aureus, S. agalactiae and L. monocytogenes) |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1148, |
| Name | 21468208 |
| N-Terminal modification | Nisin A |
| C-Terminal Modification | I-(Dhb)-AI-(Dha)-LA-(Abu)-PGAK-(Abu)-GALMGANMK-(Abu)-A-(Abu)-ANASIHV-(Dha)-K |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Dha= Didehydroalanine, Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid, Lanthionine (Ala-S-Ala) formation from 3-7 Ala, and β-methyllanthionine (Abu-S-Ala) from 8-11, 13-19, 23-26, 25-28 in between Abu and Ala |
| Chirality | Cyclic (5 hinge region due to presence of lanthion |
| Nature | 34 |
| Source | L |
| Species | Natural |
| Strain | Produced by Lactococcus lactis |
| Inhibition Concentration | Mycobacterium avium |
| In Vitro/ In vivo | Mycobacterium avium paratuberculosis (ATCC 19698) |
| Inhibition Concentration | In vitro |
| Sequence | 2010 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | None |
| Year of Publication | Antibacterial (Shigella, Pseudomonas and Salmonella, S. aureus, S. agalactiae and L. monocytogenes) |
Tertiary Structure
(Technique) | Not Predicted), |